TN2013000455A1 - FORMULATION FOR ANTI-α4β7 ANTIBODY - Google Patents
FORMULATION FOR ANTI-α4β7 ANTIBODYInfo
- Publication number
- TN2013000455A1 TN2013000455A1 TNP2013000455A TN2013000455A TN2013000455A1 TN 2013000455 A1 TN2013000455 A1 TN 2013000455A1 TN P2013000455 A TNP2013000455 A TN P2013000455A TN 2013000455 A TN2013000455 A TN 2013000455A TN 2013000455 A1 TN2013000455 A1 TN 2013000455A1
- Authority
- TN
- Tunisia
- Prior art keywords
- antibody
- formulations
- formulation
- chelator
- antioxidant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Antibody formulations are described comprising a mixture of an anti-α4β7antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544054P | 2011-10-06 | 2011-10-06 | |
| PCT/US2012/036069 WO2012151247A2 (en) | 2011-05-02 | 2012-05-02 | FORMULATION FOR ANTI-α4β7 ANTIBODY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000455A1 true TN2013000455A1 (en) | 2015-03-30 |
Family
ID=54359602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000455A TN2013000455A1 (en) | 2011-10-06 | 2013-10-31 | FORMULATION FOR ANTI-α4β7 ANTIBODY |
Country Status (2)
| Country | Link |
|---|---|
| EA (1) | EA201990056A1 (en) |
| TN (1) | TN2013000455A1 (en) |
-
2012
- 2012-05-02 EA EA201990056A patent/EA201990056A1/en unknown
-
2013
- 2013-10-31 TN TNP2013000455A patent/TN2013000455A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201990056A1 (en) | 2019-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501662A1 (en) | FORMULATION FOR ANTI-a4á7 ANTIBODY | |
| PH12020500336A1 (en) | FORMULATION FOR ANTI-a4á7 ANTIBODY | |
| NZ727516A (en) | Treatment of ocular neovascularization using a recombinant virus containing a nucleic acid encoding a vegf inhibitor | |
| MX348823B (en) | Stable formulations of linaclotide. | |
| NZ708821A (en) | Lfa-1 inhibitor formulations | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| TN2013000455A1 (en) | FORMULATION FOR ANTI-α4β7 ANTIBODY | |
| TN2013000442A1 (en) | FORMULATION FOR ANTI-α4β7 ANTIBODY | |
| UA112984C2 (en) | COMPOSITION OF ANTI-α4β7 ANTIBODY |